Switching from Mounjaro to Semaglutide: What Actually Changes

The misconception worth clearing up first: these aren't interchangeable versions of the same drug

The most common assumption when people ask about switching is that Mounjaro and semaglutide are essentially similar, so moving between them is like changing supermarket brands of the same product. That isn't accurate. Mounjaro (tirzepatide) activates two separate gut-hormone receptors (GIP and GLP-1) making it the only dual-agonist weight-loss medicine currently licensed in the UK. Semaglutide, sold for weight management as Wegovy, works on the GLP-1 receptor alone.

That difference matters when switching in either direction. Your system has been responding to a dual signal; it now receives a single one. The practical effect varies from person to person, and there is no universal rule about whether weight loss accelerates, slows, or stays roughly the same. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced a greater average weight reduction over 72 weeks than semaglutide 2.4mg. That trial compared the two at their respective maintenance doses in adults with obesity who had not previously taken either medicine, so it doesn't directly answer what happens when someone who has been stable on one medicine moves to the other. The NICE appraisal of tirzepatide (TA1026) and the NICE appraisal of semaglutide (TA875) both address clinical suitability rather than sequencing, so your prescriber draws on clinical judgement rather than a clear protocol for exactly this situation.

The point isn't that one medicine is better. It's that they're distinct, and a switch needs thought. If you're curious how the two medicines compare on results and tolerability side by side, our semaglutide vs Mounjaro comparison covers the evidence in more detail.

Why people actually switch, and what a prescriber looks at

Reasons for switching from Mounjaro to semaglutide vary widely. Some people experience side effects on tirzepatide that they find genuinely difficult to manage (persistent nausea, GI discomfort) and want to try whether a GLP-1-only medicine suits them better. Others switch because of availability, because their prescriber recommends it based on a changing health picture, or because the cost of a specific dose has shifted. Occasionally people move the other direction: if you're wondering whether switching from semaglutide to tirzepatide makes sense, the considerations are broadly the same in reverse.

A prescriber assessing a switch will typically want to know how long you've been on your current dose, whether you're still losing weight or have plateaued, what side effects you've had, and any changes to your health since you started. There's also a timing question: because both medicines affect gastric emptying and appetite through overlapping pathways, there's usually a period of adjustment when one is stopped and the other started. The prescriber decides the gap and the starting dose for the new medicine, which may not be the maintenance dose you were on before. Starting semaglutide mid-journey doesn't mean beginning at 2.4mg.

If you've been managing well on Mounjaro but are simply curious about the practical steps involved in switching to semaglutide, that page goes through the process specifically.

How these two medicines compare on paper

The table below draws from the licensed indications, NICE appraisals, and published trial data. Numbers are hedged where appropriate; your individual results depend on the dose reached, lifestyle factors, and how your body responds.

Ozempic is also semaglutide, but it is licensed for type 2 diabetes, not weight management. It should not be sought or used for weight loss, and if you're looking at a switch from Ozempic to Mounjaro, the licensing difference is the first thing a prescriber addresses. Similarly, Rybelsus tablets are oral semaglutide at doses licensed for diabetes only, not the same as Wegovy tablets.

For a detailed look at how the cost of these two medicines compares across doses and providers, the Mounjaro and Wegovy price comparison sets that out plainly.

What switching looks like at a regulated UK pharmacy

At nume, every treatment decision (including a switch) goes through a GPhC-registered Independent Prescriber who reads your consultation the same day. If you're transferring from another provider, our prescribers ask for evidence of your current treatment and dose; we don't simply issue a prescription for whichever medicine you name. That might feel like an extra step. It exists because a switch between two different receptor pathways at the wrong dose, or without a proper wash-out period, can produce unnecessary side effects.

Once approved, the treatment ships the same day on orders placed before 12pm, arriving via DPD the next working day in plain packaging with no indication of what's inside. The pen itself (whether Mounjaro's KwikPen or Wegovy's pre-filled injector) comes with full labelling and the patient information leaflet, which covers storage and administration. That leaflet is the right place for questions about injection technique, not a forum.

Our clinical team reviews all repeat orders before dispatch. You can read more about how we're structured or see the Wegovy vs Mounjaro overview if you'd like to read more before starting a consultation. Which medicine suits you is a clinical decision our prescribers make with you.